Rare disease
Waldenstrom's Macroglobulinaemia
Clinical trials recruiting in Australia for Waldenstrom's Macroglobulinaemia, a rare disease, as the public registries list them.
Also called: WM; Waldenstrom macroglobulinemia; Waldenström macroglobulinemia; Macroglobulinemia of Waldenstrom; Lymphoplasmacytic lymphoma with IgM gammopathy; Primary macroglobulinemia
Follow this condition Browse A to Z Browse by body system
At a glance
5 trials recruiting in Australia
52 trials recruiting overseas
Unknown (Point prevalence, Worldwide, Validated) prevalence
Elderly age of onset
15 October 2026 date last checked
Trials in Australia
This Australian count is likely to be on the low side. It counts the trials this site files under this condition; the registry’s own search is broader and also returns closely related conditions, some of which have their own page here. If you are searching widely, check the registry as well — every trial below links to its own record.
-
Recruiting Phase 2
Phase 2 study for people with Waldenstrom's Macroglobulinaemia
Where- Nepean Hospital-Nepean Cancer Care Centre ( Site 0204), Sydney (NSW) — Completed
- Box Hill Hospital ( Site 0203), Box Hill (VIC) — Recruiting
- Sir Charles Gairdner Hospital ( Site 0200), Nedlands (WA) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Merck Sharp & Dohme LLCTimelineStarted 5 April 2021 Today 16 October 2026 Estimated completion 4 January 2029NCT04728893 · Checked 15 October 2026
-
Recruiting Phase 2
Phase 2 study for people with Waldenstrom's Macroglobulinaemia
Where- Concord Repatriation General Hospital, Concord (NSW) — Recruiting
- Calvary Mater Newcastle, Waratah (NSW) — Recruiting
- Princess Alexandra Hospital, Woolloongabba (QLD) — Recruiting
- St Vincents Hospital Melbourne, Fitzroy (VIC) — Recruiting
- Austin Health, Heidelberg (VIC) — Recruiting
- Peter Maccallum Cancer Centre, Melbourne (VIC) — Recruiting
- The Alfred Hospital, Melbourne (VIC) — Recruiting
- Linear Clinical Research, Nedlands (WA) — Recruiting
- Perth Blood Institute, West Perth (WA) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor BeOne MedicinesTimelineStarted 13 September 2021 Today 16 October 2026 Estimated completion 1 March 2027NCT05006716 · Checked 12 October 2026
-
Recruiting Phase 1
Phase 1 study for people with Waldenstrom's Macroglobulinaemia
Where- The Alfred Hospital, Melbourne, VIC (VIC) — Not yet recruiting
- Linear Clinical Research, Nedlands (WA) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Eli Lilly and CompanyTimelineStarted 28 May 2026 Today 16 October 2026 Estimated completion 1 April 2027NCT07101328 · Checked 15 October 2026
-
Recruiting Phase 2
Phase 2 study for people with Waldenstrom's Macroglobulinaemia
Where- Epworth HealthCare, Richmond (VIC) — Recruiting
- Linear Clinical Research, Nedlands (WA) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor ModeX Therapeutics, An OPKO Health CompanyTimelineStarted 13 April 2026 Today 16 October 2026 Estimated completion 1 January 2028NCT07249905 · Checked 11 October 2026
-
Recruiting Phase 1
Phase 1 study for people with Waldenstrom's Macroglobulinaemia
Where- Monash Health, Clayton (VIC) — Not yet recruiting
- Austin Health, Melbourne (VIC) — Not yet recruiting
- Linear Clinical Research, Nedlands (WA) — Recruiting
- Gold Coast Hospital, Southport (QLD) — Not yet recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Taiho Oncology, Inc.TimelineStarted 22 June 2026 Today 16 October 2026 Estimated completion 1 January 2029NCT07691606 · Checked 15 October 2026
Trials overseas
52 trials for this disease are open to new participants outside Australia, as ClinicalTrials.gov listed them on 11 October 2026. Voxsanity does not publish a page for any of them; the searches below reach them at the registry.
These overseas counts are likely too high. They come from the registry’s own search, which expands a condition name to related conditions, so some of the trials counted are for a different disease in the same family.
Search ClinicalTrials.gov Search the WHO registry portal Joining a trial overseas
Trials not shown here
Some Australian trials are registered only on the Australian New Zealand Clinical Trials Registry and are not shown here. Search them at Australian Clinical Trials.
Key facts
Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com).
About Waldenstrom's Macroglobulinaemia
The text below is reproduced exactly as its source published it. It has not been edited, shortened or rewritten.
Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow. These abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and more mature cells derived from B cells known as plasma cells. These abnormal cells with both lymphocyte and plasma characteristics are known as lymphoplasmacytic cells. Due to these cells, Waldenström macroglobulinemia is classified as a lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, these abnormal cells produce excess amounts of IgM, the largest of a type of protein known as an immunoglobulin; the overproduction of this large protein contributes to the condition's name (macroglobulinemia). Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer. Some affected individuals have elevated levels of IgM and lymphoplasmacytic cells but no symptoms of the condition; in these cases, the disease is usually found incidentally by a blood test taken for another reason. These individuals are diagnosed with smoldering (or asymptomatic) Waldenström macroglobulinemia. It can be many years before a person with the condition develops noticable signs and symptoms. The most common signs and symptoms to first appear in people with Waldenström macroglobulinemia are weakness and extreme tiredness (fatigue) caused by a shortage of red blood cells (anemia). Affected individuals can also experience general symptoms such as fever, night sweats, and weight loss. Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy). Doctors are unsure why this feature occurs, although they speculate that the IgM protein attaches to the protective covering of nerve cells (myelin) and breaks it down. The damaged nerves cannot carry signals normally, leading to neuropathy. Other features of Waldenström macroglobulinemia are due to the accumulation of lymphoplasmacytic cells in different tissues. For example, accumulation of these cells can lead to an enlarged liver (hepatomegaly), spleen (splenomegaly), or lymph nodes (lymphadenopathy). In the bone marrow, the lymphoplasmacytic cells interfere with normal blood cell development, causing a shortage of healthy blood cells (pancytopenia). Several other signs and symptoms of Waldenström macroglobulinemia are related to the excess amounts of IgM. Increased IgM can thicken blood and impair circulation, causing a condition known as hyperviscosity syndrome. Features related to hyperviscosity syndrome include bleeding in the nose or mouth, blurring or loss of vision, headache, dizziness, and confusion. In some affected individuals, IgM and other immunoglobulins react to cold temperatures to form gel-like clumps that block blood flow in areas exposed to the cold, such as the hands and feet. These clumped proteins are referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures. The IgM protein, along with another protein called amyloid, can build up in organs and interfere with their normal function. This buildup causes a condition called amyloidosis. Organs that are typically affected by amyloidosis include the heart, kidneys, liver or spleen. Affected individuals can experience weakness, fatigue, shortness of breath, irregular heartbeat, or joint pain.
US source; availability in Australia may differ.
Source: MedlinePlus Genetics (medlineplus.gov), public domain (U.S. National Library of Medicine). Read the full source.
Sources and dates
- ClinicalTrials.gov – trial records, statuses and site lists
- MedlinePlus – the About text above, reproduced exactly
- Orphanet / Orphadata – prevalence, age of onset, inheritance, genes and alternative names, used under CC BY 4.0
- ClinicalTrials.gov processing date: 15 October 2026.
- This page last checked by Voxsanity: 15 October 2026.
Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.
Not medical advice.
Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.
Orphanet citation
Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com). Accessed 20 September 2026.
Waldenstrom's Macroglobulinaemia is one of the rare diseases tracked on the Voxsanity rare disease hub, where you can compare it with every other rare condition we follow and filter trials by country.
Tell us which conditions matter to you
We use requests to help decide what to add next. Telling us about a condition is not a promise that we will add it, and we cannot say when any condition might appear.